&nbsp;

DerekMcNally.jpg

Aug 2023

Données sur l’utilisation des médicaments biosimilaires en oncologie

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Status: Current
ID: PET 2023-1

Nov 2023

Regimen

DOST(MNT); CRBPPACL+DOST

Cancer Type:

Gynecologic,

Endometrial

Intent: Adjuvant, Curative, Palliative

Funding:

New Drug Funding Program

Dostarlimab - Primary Advanced or Recurrent MSI-H or dMMR Endometrial Cancer

, Collapse Show fewer tags

Drugs Used:

Quick Link(s):

Regimen Monograph

May 2025

Regimen

EPCO; EPCO(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Epcoritamab (Outpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

High Cost Therapy Funding Program

Epcoritamab (Inpatient) - Relapsed or Refractory Diffuse Large B-Cell Lymphoma

, Collapse Show fewer tags

Drugs Used:

epcoritamab

... Show more tags

Quick Link(s):

Regimen Monograph

Aug 2025

Document

dapColorectal15Feb2024.xml

Feb 2024

Document

dapColorectal15Feb2024.html

Feb 2024

Document

dapProstate15Feb2024.xml

Feb 2024

Document

dapProstate15Feb2024.html

Feb 2024

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2023

Status: Current
Version: PET 2023-2

Jun 2024

Document